Cara Therapeutics, Inc. (NASDAQ:CARA – Get Free Report) saw a large increase in short interest in the month of September. As of September 15th, there was short interest totalling 1,210,000 shares, an increase of 9.0% from the August 31st total of 1,110,000 shares. Currently, 2.6% of the shares of the stock are sold short. Based on an average daily volume of 705,600 shares, the days-to-cover ratio is currently 1.7 days.
Cara Therapeutics Price Performance
NASDAQ CARA traded up $0.02 on Friday, hitting $0.31. 645,339 shares of the company were exchanged, compared to its average volume of 660,258. Cara Therapeutics has a twelve month low of $0.24 and a twelve month high of $1.74. The firm has a market capitalization of $16.68 million, a P/E ratio of -0.14 and a beta of 0.70. The company’s 50 day moving average price is $0.33 and its 200-day moving average price is $0.52.
Cara Therapeutics (NASDAQ:CARA – Get Free Report) last issued its quarterly earnings results on Wednesday, August 14th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.10). Cara Therapeutics had a negative net margin of 1,010.20% and a negative return on equity of 241.31%. The firm had revenue of $0.99 million during the quarter, compared to analysts’ expectations of $1.26 million. As a group, equities analysts expect that Cara Therapeutics will post -1.24 EPS for the current year.
Analyst Upgrades and Downgrades
Read Our Latest Report on Cara Therapeutics
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Cara Therapeutics stock. Marquette Asset Management LLC acquired a new position in shares of Cara Therapeutics, Inc. (NASDAQ:CARA – Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 94,238 shares of the biopharmaceutical company’s stock, valued at approximately $86,000. Marquette Asset Management LLC owned 0.17% of Cara Therapeutics at the end of the most recent quarter. 44.66% of the stock is currently owned by institutional investors and hedge funds.
Cara Therapeutics Company Profile
Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.
Recommended Stories
- Five stocks we like better than Cara Therapeutics
- Investing In Preferred Stock vs. Common Stock
- Simon Property REIT: A Safe Bet for Growth and Steady Dividends
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- CarMax’s Impressive Rally: What Investors Should Watch Next
- Compound Interest and Why It Matters When Investing
- MarketBeat Week in Review – 9/23 – 9/27
Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.